Compare IDEXX Laboratories, Inc. (IDXX) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs MPLX LP — how do they compare? IDEXX Laboratories, Inc. trades at $551.53 (market cap $44.48B), while MPLX LP trades at $56.67 (market cap $57.97B). The key difference: MPLX LP is the larger of the two by market cap, and MPLX LP pays a 7.54% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MPLX | |
|---|---|---|
Market Cap | $44.48B | $57.97B |
Sector | Health | Technology |
52-Week High | $766.68 | $59.17 |
52-Week Low | $520.87 | $47.80 |
Enterprise Value | $45.38B | $82.60B |
Dividend Yield | — | 7.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
MPLX trades at $57.13, up 0.12% today, with a bullish technical signal from moving averages and a consensus analyst price target of $60.00. The company reported strong profitability with a 41.24% net income margin in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights its resilient midstream model and attractive dividend yield.
The outlook for MPLX is positive, supported by stable cash flows, a high dividend yield, and analyst optimism. Key risks include exposure to energy market volatility and a recent earnings miss. The stock offers value with a P/E of 12.35 and strong institutional buy ratings, but investors should monitor execution on growth projects and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
